Skip to main content
Erschienen in: Journal of Neurology 2/2016

01.02.2016 | Original Communication

The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS

verfasst von: Douglas R. Jeffery, Elisabetta Verdun Di Cantogno, Shannon Ritter, Daniela Piani Meier, Ernst-Wilhelm Radue, William Camu

Erschienen in: Journal of Neurology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Clinical evidence in patients with relapsing-remitting multiple sclerosis suggests an association between MRI outcome measures and disability progression (DP). Post hoc analysis to investigate the association and potential predictive value of brain volume loss (BVL) with long-term DP in FREEDOMS. Patients were categorized into quartiles by SIENA-calculated percent brain volume change from baseline to month (M) 24. Patient characteristics at baseline were determined for each quartile, as were the proportions of patients at M24 and M48 reaching Expanded Disability Status Scale (EDSS) scores of ≥4.0 or ≥6.0 or DP confirmed at 3 months (CDP3) or 6 months (CDP6), and change in EDSS and Multiple Sclerosis Functional Composite. MS disease activity and severity as well as brain volume at baseline were predictive of subsequent BVL over 24 months. The quartiles of patients with greater BVL at 24 months were at highest risk (odds ratio, p value) for reaching EDSS ≥4 (2.8, p = 0.001) or ≥6 (5.73, p = 0.0005) and experienced more DP at M24 (CDP3 2.13, p = 0.002; CDP6 2.17, p = 0.003) and M48 (CDP3 1.98, p = 0.006; CDP6 1.87, p = 0.018) compared to the quartile of patients with the least amount of BVL. These findings confirm the clinical relevance of early brain volume changes for long-term DP.
Literatur
1.
Zurück zum Zitat Rudick RA, Fisher E (2013) Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): yes. Mult Scler 19:1003–1004CrossRefPubMed Rudick RA, Fisher E (2013) Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): yes. Mult Scler 19:1003–1004CrossRefPubMed
2.
Zurück zum Zitat De Stefano N, Airas L, Grigoriadis N et al (2014) Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 28:147–156CrossRefPubMed De Stefano N, Airas L, Grigoriadis N et al (2014) Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 28:147–156CrossRefPubMed
3.
Zurück zum Zitat Filippi M, Rocca MA, Barkhof F et al (2012) Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 11:349–360CrossRefPubMed Filippi M, Rocca MA, Barkhof F et al (2012) Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 11:349–360CrossRefPubMed
4.
Zurück zum Zitat Siffrin V, Vogt J, Radbruch H et al (2010) Multiple sclerosis—candidate mechanisms underlying CNS atrophy. Trends Neurosci 33:202–210CrossRefPubMed Siffrin V, Vogt J, Radbruch H et al (2010) Multiple sclerosis—candidate mechanisms underlying CNS atrophy. Trends Neurosci 33:202–210CrossRefPubMed
5.
Zurück zum Zitat Kuhlmann T, Lingfeld G, Bitsch A et al (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125:2202–2212CrossRefPubMed Kuhlmann T, Lingfeld G, Bitsch A et al (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125:2202–2212CrossRefPubMed
6.
Zurück zum Zitat Bermel RA, Bakshi R (2006) The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 5:158–170CrossRefPubMed Bermel RA, Bakshi R (2006) The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 5:158–170CrossRefPubMed
7.
Zurück zum Zitat Bakshi R, Benedict RH, Bermel RA et al (2001) Regional brain atrophy is associated with physical disability in multiple sclerosis: semiquantitative magnetic resonance imaging and relationship to clinical findings. J Neuroimaging 11:129–136CrossRefPubMed Bakshi R, Benedict RH, Bermel RA et al (2001) Regional brain atrophy is associated with physical disability in multiple sclerosis: semiquantitative magnetic resonance imaging and relationship to clinical findings. J Neuroimaging 11:129–136CrossRefPubMed
8.
Zurück zum Zitat Benedict RH, Carone DA, Bakshi R (2004) Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis. J Neuroimaging 14:36s–45sCrossRefPubMed Benedict RH, Carone DA, Bakshi R (2004) Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis. J Neuroimaging 14:36s–45sCrossRefPubMed
9.
Zurück zum Zitat Jacobsen C, Hagemeier J, Myhr KM et al (2014) Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. J Neurol Neurosurg Psychiatry 85:1109–1115CrossRefPubMed Jacobsen C, Hagemeier J, Myhr KM et al (2014) Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. J Neurol Neurosurg Psychiatry 85:1109–1115CrossRefPubMed
10.
Zurück zum Zitat Simon JH, Jacobs LD, Campion MK et al (1999) A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group MSCRG. Neurology 53:139–148CrossRefPubMed Simon JH, Jacobs LD, Campion MK et al (1999) A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group MSCRG. Neurology 53:139–148CrossRefPubMed
11.
Zurück zum Zitat Zivadinov R, Bakshi R (2004) Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging 14:27s–35sCrossRefPubMed Zivadinov R, Bakshi R (2004) Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging 14:27s–35sCrossRefPubMed
12.
Zurück zum Zitat Zivadinov R, Sepcic J, Nasuelli D et al (2001) A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 70:773–780CrossRefPubMedPubMedCentral Zivadinov R, Sepcic J, Nasuelli D et al (2001) A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 70:773–780CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Kappos L, Radue EW, O’Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387–401CrossRefPubMed Kappos L, Radue EW, O’Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387–401CrossRefPubMed
14.
Zurück zum Zitat Calabresi PA, Radue EW, Goodin D et al (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 13:545–556CrossRefPubMed Calabresi PA, Radue EW, Goodin D et al (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 13:545–556CrossRefPubMed
15.
Zurück zum Zitat Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402–415CrossRefPubMed Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402–415CrossRefPubMed
16.
Zurück zum Zitat Cohen J, Radue E-W, Barkhof F et al (2013) Fingolimod-effect on brain atrophy and clinical/MRI correlations in three phase 3 studies—TRANSFORMS, FREEDOMS and FREEDOMS II. Neurology 80: Meeting Abstracts 1 S51.006 Cohen J, Radue E-W, Barkhof F et al (2013) Fingolimod-effect on brain atrophy and clinical/MRI correlations in three phase 3 studies—TRANSFORMS, FREEDOMS and FREEDOMS II. Neurology 80: Meeting Abstracts 1 S51.006
17.
Zurück zum Zitat Radue EW, O’Connor P, Polman CH et al (2012) Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol 69:1259–1269CrossRefPubMed Radue EW, O’Connor P, Polman CH et al (2012) Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol 69:1259–1269CrossRefPubMed
18.
Zurück zum Zitat Sormani MP, Arnold DL, De Stefano N (2014) Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 75:43–49CrossRefPubMed Sormani MP, Arnold DL, De Stefano N (2014) Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 75:43–49CrossRefPubMed
19.
Zurück zum Zitat Sormani M, De Stefano N, Francis G et al (2015) Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler 21(7):916–924CrossRefPubMed Sormani M, De Stefano N, Francis G et al (2015) Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler 21(7):916–924CrossRefPubMed
21.
Zurück zum Zitat Smith SM, Zhang Y, Jenkinson M et al (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17:479–489CrossRefPubMed Smith SM, Zhang Y, Jenkinson M et al (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17:479–489CrossRefPubMed
22.
Zurück zum Zitat Rudick RA, Cutter G, Reingold S (2002) The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials. Mult Scler 8:359–365CrossRefPubMed Rudick RA, Cutter G, Reingold S (2002) The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials. Mult Scler 8:359–365CrossRefPubMed
23.
Zurück zum Zitat Ozakbas S, Cagiran I, Ormeci B et al (2004) Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis. J Neurol Sci 218:3–7CrossRefPubMed Ozakbas S, Cagiran I, Ormeci B et al (2004) Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis. J Neurol Sci 218:3–7CrossRefPubMed
24.
Zurück zum Zitat Sumowski JF, Chiaravalloti N, DeLuca J (2009) Cognitive reserve protects against cognitive dysfunction in multiple sclerosis. J Clin Exp Neuropsychol 31:913–926CrossRefPubMed Sumowski JF, Chiaravalloti N, DeLuca J (2009) Cognitive reserve protects against cognitive dysfunction in multiple sclerosis. J Clin Exp Neuropsychol 31:913–926CrossRefPubMed
25.
Zurück zum Zitat Sumowski JF, Chiaravalloti N, Wylie G et al (2009) Cognitive reserve moderates the negative effect of brain atrophy on cognitive efficiency in multiple sclerosis. J Int Neuropsychol Soc 15:606–612CrossRefPubMed Sumowski JF, Chiaravalloti N, Wylie G et al (2009) Cognitive reserve moderates the negative effect of brain atrophy on cognitive efficiency in multiple sclerosis. J Int Neuropsychol Soc 15:606–612CrossRefPubMed
26.
Zurück zum Zitat Sumowski JF, Leavitt VM (2013) Cognitive reserve in multiple sclerosis. Mult Scler 19:1122–1127CrossRefPubMed Sumowski JF, Leavitt VM (2013) Cognitive reserve in multiple sclerosis. Mult Scler 19:1122–1127CrossRefPubMed
27.
Zurück zum Zitat Sumowski JF, Rocca MA, Leavitt VM et al (2013) Brain reserve and cognitive reserve in multiple sclerosis: what you’ve got and how you use it. Neurology 80:2186–2193CrossRefPubMedPubMedCentral Sumowski JF, Rocca MA, Leavitt VM et al (2013) Brain reserve and cognitive reserve in multiple sclerosis: what you’ve got and how you use it. Neurology 80:2186–2193CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Amato MP, Ponziani G, Amaducci L (1999) Cognitive impairment in multiple sclerosis: a longitudinal study. Electroencephalogr Clin Neurophysiol Suppl 50:465–468 Amato MP, Ponziani G, Amaducci L (1999) Cognitive impairment in multiple sclerosis: a longitudinal study. Electroencephalogr Clin Neurophysiol Suppl 50:465–468
29.
Zurück zum Zitat Schwartz CE, Quaranto BR, Healy BC et al (2013) Cognitive reserve and symptom experience in multiple sclerosis: a buffer to disability progression over time? Arch Phys Med Rehabil 94:1971–1981CrossRefPubMed Schwartz CE, Quaranto BR, Healy BC et al (2013) Cognitive reserve and symptom experience in multiple sclerosis: a buffer to disability progression over time? Arch Phys Med Rehabil 94:1971–1981CrossRefPubMed
30.
Zurück zum Zitat Fisher E, Rudick RA, Simon JH et al (2002) Eight-year follow-up study of brain atrophy in patients with MS. Neurology 59:1412–1420CrossRefPubMed Fisher E, Rudick RA, Simon JH et al (2002) Eight-year follow-up study of brain atrophy in patients with MS. Neurology 59:1412–1420CrossRefPubMed
31.
Zurück zum Zitat Di Filippo M, Anderson VM, Altmann DR et al (2010) Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 81:204–208CrossRefPubMed Di Filippo M, Anderson VM, Altmann DR et al (2010) Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 81:204–208CrossRefPubMed
32.
Zurück zum Zitat Lukas C, Minneboo A, de Groot V et al (2010) Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. J Neurol Neurosurg Psychiatry 81:1351–1356CrossRefPubMed Lukas C, Minneboo A, de Groot V et al (2010) Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. J Neurol Neurosurg Psychiatry 81:1351–1356CrossRefPubMed
33.
Zurück zum Zitat Popescu V, Agosta F, Hulst HE et al (2013) Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 84:1082–1091CrossRefPubMed Popescu V, Agosta F, Hulst HE et al (2013) Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 84:1082–1091CrossRefPubMed
34.
Zurück zum Zitat Goodin DS, Traboulsee A, Knappertz V et al (2012) Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry 83:282–287CrossRefPubMed Goodin DS, Traboulsee A, Knappertz V et al (2012) Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry 83:282–287CrossRefPubMed
35.
Zurück zum Zitat Bermel RA, You X, Foulds P et al (2013) Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol 73:95–103CrossRefPubMed Bermel RA, You X, Foulds P et al (2013) Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol 73:95–103CrossRefPubMed
Metadaten
Titel
The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS
verfasst von
Douglas R. Jeffery
Elisabetta Verdun Di Cantogno
Shannon Ritter
Daniela Piani Meier
Ernst-Wilhelm Radue
William Camu
Publikationsdatum
01.02.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 2/2016
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-7959-1

Weitere Artikel der Ausgabe 2/2016

Journal of Neurology 2/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.